Abstract

Commentary had biological markers of present and/or past HBV or HCV infection was 9.7%, Liver dysfunction in patients with a level similar to that of the local reference general population and lower than in IBD under immunosuppressive previously published series. The authors also pointed out the low prevalence (12%) treatment: do we need to fear? of patients with IBD with effective HBV vaccination, and observed that transfusion 1 2 was no longer a significant risk factor for Laurent Beaugerie, Alexander L Gerbes HCV infection as soon as HCV markers became mandatory in blood banks. In this issue of Gut (see page 1340), There is an ineluctable trend in the treat- are low (3% and 1.4%, respectively) ), and the same Spanish REPENTINA group ment of inflammatory bowel disease that dose adaptation is most cases is addressed the question of the prevalence (IBD) towards an extensive use of immu- sufficient to resolve the problem. and risk factors for liver dysfunction (LD) nosuppressive drugs. These agents are However, a safety signal of thiopurine- related to hepatitis B and C in patients prescribed earlier in the disease, in an induced injury of endothelial cells, essen- with IBD receiving immunosuppressive increased proportion of